Alterity Therapeutics Limited (ATHE) is a biotechnology company specializing in the development of therapeutic drugs for neurodegenerative diseases, with a primary focus on Parkinsonian disorders and related movement disorders. The company is a development-stage enterprise, advancing its pharmaceutical products through early to mid-stage clinical trials. Alterity does not sell commercial products but generates revenue through government grants, licensing, research collaborations, and interest income.
- Research and Development in Neurodegenerative Diseases - Focuses on discovering and developing therapeutic drugs targeting Parkinsonian disorders, including Multiple System Atrophy (MSA), a rare and debilitating condition with no approved treatments.
- ATH434 - Lead drug candidate in Phase 2 clinical trials for MSA, designed to address the underlying pathology of the disease.
- PBT2 - Previously developed for Alzheimer’s and Huntington diseases, with completed Phase 1 and Phase 2 trials.
- Discovery Platform - Maintains a chemical library of over 1,000 validated compounds designed for oral bioavailability and blood-brain barrier penetration, targeting the interrelationship of metals and proteins in neurodegenerative diseases.
- Collaborative Research - Partners with leading scientists and institutions, conducting research at The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Dr. David Stamler Executive | Chief Executive Officer | None | Dr. Stamler has extensive experience in drug development, previously serving as CMO at Alterity and leading the development of ATH434 for neurodegenerative diseases. | View Report → |
Mr. Phillip Hains Executive | Chief Financial Officer and Company Secretary | Operates within Acclime Australia (formerly The CFO Solution) | Mr. Hains has over 30 years of experience in financial reporting and compliance, specializing in supporting public companies. | |
Mr. Brian Meltzer Board | Director | Director of Australia-Israel Chamber of Commerce; Chairman of Independence Australia | Mr. Meltzer has a background in investment banking and corporate advisory, with expertise in property transactions, venture capital, and syndications. | |
Mr. Geoffrey Kempler Board | Chairman of the Board | Chair of Hexima Ltd; Member of Turner Institute Advisory Board at Monash University | Founder of Alterity, Mr. Kempler has a background in psychology and investment, with significant contributions to the company's strategic direction. | |
Mr. Lawrence Gozlan Board | Director | Chief Investment Officer at Scientia Capital; Director of Opthea Limited | Mr. Gozlan is a life sciences investment specialist, leading Scientia Capital and holding directorships in several biotech companies. | |
Mr. Peter Marks Board | Director | Chairman of Newburyport Partners; Director of Noxopharm Limited, Iris Metals Limited, and Evergreen Lithium Limited | Mr. Marks has over 35 years of experience in corporate advisory and investment banking, focusing on life sciences and high-tech sectors. |
Research analysts covering ALTERITY THERAPEUTICS.
Recent press releases and 8-K filings for ATHE.
Alterity Therapeutics Ltd to Vote on Share Issuance Ratification, Equity Plans, and Director Re-election
·$ATHEExecutive Compensation
New Projects/Investments
- Shareholders will vote on the ratification of 1,666,666,663 Placement Shares issued on September 15, 2025, at $0.012 each, which raised $20 million for non-clinical studies, chemical manufacturing and controls (CMC) activities, clinical and regulatory activities for ATH434 in MSA, and general working capital.
- The company is seeking approval for the issue of up to 500,000,000 Incentives under the 2004 ASX Plan and up to 500,000,000 Incentives under the 2018 ADS Plan, as well as an additional 10% placement capacity which could allow for the issuance of approximately 1,087,541,632 Equity Securities based on shares outstanding as of October 14, 2025.
- Shareholders will also vote on the re-election of Mr. Brian Meltzer as a Director and the adoption of a new Constitution.
Oct 21, 2025, 10:51 AM
Alterity Therapeutics Presents Positive ATH434 Phase 2 Trial Data for MSA
·$ATHEProduct Launch
New Projects/Investments
- Alterity Therapeutics presented positive data from its ATH434 Phase 2 clinical trial for Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson’s Disease and Movement Disorders on October 9, 2025.
- The trial data demonstrated that ATH434 slows disease progression and stabilizes orthostatic hypotension in MSA patients.
- Treatment with ATH434 resulted in a clinically significant reduction in disease severity on the modified UMSARS I scale, showing a 48% relative treatment effect at the 50 mg dose and a 30% relative treatment effect at the 75 mg dose at 52 weeks.
- A new analysis, accounting for baseline differences, strengthened the efficacy signal for the 75 mg dose to a 35% relative treatment effect.
- ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed to the drug. It has also been granted Fast Track Designation and Orphan Drug Designation by the FDA and European Commission for MSA.
Oct 9, 2025, 10:33 AM
Alterity Therapeutics to Present Positive Phase 2 Data for ATH434 at MDS Conference
·$ATHENew Projects/Investments
- Alterity Therapeutics (ATHE) announced it will present positive data from its ATH434-201 double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson's Disease and Movement Disorders (MDS) from October 5-9, 2025.
- The presentations will include an oral platform presentation by CEO David Stamler, M.D., on October 8, 2025, highlighting that ATH434 slowed disease progression in the Phase 2 study.
- The Phase 2 trial demonstrated robust clinical efficacy, target engagement on key biomarkers, and a favorable safety profile for ATH434, showing clinically and statistically significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I.
- ATH434, Alterity's lead candidate, has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation from the FDA and the European Commission for the treatment of MSA.
Oct 2, 2025, 10:26 AM
Alterity Therapeutics Presents Positive Phase 2 Data for ATH434 in MSA
·$ATHEProduct Launch
New Projects/Investments
- Alterity Therapeutics presented positive data from its ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA) at the American Neurological Association Annual Meeting on September 15, 2025.
- The study demonstrated clinically meaningful efficacy in modifying disease progression at both 50 mg and 75 mg doses, showing clinically and statistically significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I.
- ATH434 was well tolerated with similar adverse event rates as placebo, and no serious adverse events were attributed to the study drug.
- The drug also showed target engagement by reducing iron accumulation in MSA affected brain regions and has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation from both the FDA and the European Commission for the treatment of MSA.
Sep 15, 2025, 12:04 PM
Alterity Therapeutics Presents Positive Phase 2 Data for ATH434-201
·$ATHE- Alterity Therapeutics presented data from its ATH434-201 randomized, double-blind Phase 2 clinical trial for Multiple System Atrophy (MSA) at the 150th Annual Meeting of the American Neurological Association.
- The study demonstrated that ATH434 slowed disease progression in MSA patients at both 50 mg and 75 mg doses, showing clinically meaningful efficacy and target engagement by reducing iron accumulation in affected brain regions.
- ATH434 was well tolerated, with adverse event rates similar to placebo and no serious adverse events attributed to the study drug.
- ATH434 has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation from both the FDA and the European Commission for MSA treatment.
Sep 15, 2025, 11:26 AM
Alterity Therapeutics Limited applies for quotation of new shares following option exercise
·$ATHEExecutive Compensation
Delisting/Listing Issues
- Alterity Therapeutics Limited applied for the quotation of 79,999,800 new Ordinary Fully Paid shares (ATH) on July 17, 2025, which were issued due to the exercise of options under an employee incentive scheme.
- These options were exercised for a cash consideration of USD 0.00300000 per security, with David Stamler, a Key Management Personnel, exercising 79,999,800 of these options.
- Following this quotation, the total number of Ordinary Fully Paid shares (ATH) will increase to 9,207,370,486.
Jul 17, 2025, 12:00 AM
Alterity Therapeutics Responds to ASX Price Query
·$ATHEDelisting/Listing Issues
New Projects/Investments
- Alterity Therapeutics Limited (ATHE) filed a 6-K on July 14, 2025, in response to an ASX price query regarding a significant increase in its share price and trading volume between July 10 and July 11, 2025.
- The company stated it is not aware of any unannounced information that could explain the recent trading activity in its securities.
- Alterity Therapeutics noted that it expects to release finalized Phase 2 data from the ATH-201 study and open-label data from the ATH-202 study in mid-year 2025, which could be contributing to market anticipation.
- An upcoming Non-Deal Roadshow is scheduled from July 31 to August 6, 2025, involving investor meetings.
Jul 14, 2025, 12:00 AM
Alterity Therapeutics Limited Reports Change in Substantial Holding
·$ATHE- Form 6-K for May 2025 filed by Alterity Therapeutics Limited under the Corporations Act 2001, reporting regulatory disclosures and significant events (document ).
- Substantial holding change details provided by The Bank of New York Mellon Corporation and its group, including adjustments in voting power of ordinary shares (document ).
- Annexures included that list share deposit, transfer details, and precise dates of changes, outlining the shifts in voting rights and interests (documents ).
May 23, 2025, 12:00 AM
Alterity Therapeutics Granted FDA Fast Track for ATH434
·$ATHENew Projects/Investments
- Alterity Therapeutics Ltd has received U.S. FDA Fast Track Designation for its lead candidate ATH434 aimed at treating Multiple System Atrophy, highlighting its potential to meet a high unmet medical need.
- This designation will allow for more frequent interactions with the FDA to facilitate an accelerated development and review process.
May 5, 2025, 12:00 AM
Alterity Therapeutics Releases Q3 FY25 Clinical and Financial Update
·$ATHENew Projects/Investments
- ATH434-201 Phase 2 trial in MSA reported positive topline data with robust clinical efficacy, supporting continued advancement in disease modifying treatment.
- The ATH434-202 open-label trial in advanced MSA was completed in March 2025, with topline results expected mid-year.
- The company maintained a strong cash position with A$17.96M on March 31, 2025, and raised an additional A$27.1M post–quarter end to further support its activities.
Apr 30, 2025, 12:00 AM